Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

To join this study, you generally need to be between 40 and 80 years old. You must have been diagnosed with Idiopathic Pulmonary Fibrosis (IPF) within the last five years, and your diagnosis needs to be confirmed by independent expert review of your lung scans.

Your lung function will also be important. Specifically, tests like FVC and DLco need to meet certain levels. If you're already taking nintedanib or pirfenidone for IPF, that's generally fine, as long as you've been on a stable dose for at least four weeks before the study starts. If you've taken these medicines in the past but stopped, you'd need to have been off them for at least four weeks.

There are also some reasons why you might not be able to join. For example, if you have other serious lung infections, if your emphysema (another lung condition) is worse than your fibrosis, or if you need to use oxygen for more than 15 hours a day. Also, if you've had a sudden worsening of your IPF in the last six months, or have certain other medical conditions involving your connective tissues, you wouldn't be able to participate.

If you decide to take part, you'll be given either the study medicine, RXC007, or a dummy treatment called a placebo. You'll take these twice a day for 12 weeks (about 3 months). During this time, you will have regular visits to the clinic to check your health, how you're feeling, and to perform different medical assessments such as blood tests, lung function tests, and possibly scans. These visits help the doctors understand how the medicine is affecting you and if you're experiencing any side effects. The total duration of your active participation will be around 12 weeks, plus some initial screening appointments and follow-up checks.